The Imminent danger of Lp(a): Time to face to challenge
Meeting report with video, highlights and slides of an EAS endorsed satellite meeting held prior to the 87th EAS congress in Maastricht, The Netherlands on the imminent danger of Lp(a) - videos will be added soon.
Episodes 1-9 of 9
- The Imminent danger of Lp(a): Time to face to challengeLp(a) and immune metabolism
Jeffrey Kroon, PhD
- The Imminent danger of Lp(a): Time to face to challengePrevalence and relevance of elevated Lp(a) in familial hypercholesterolemia
Prof. Børge Nordestgaard, MD
- The Imminent danger of Lp(a): Time to face to challengeLp(a) apheresis and CVD risk modulation
Elisa Waldmann, MD
- The Imminent danger of Lp(a): Time to face to challengeLDL vs Lp(a) cholesterol: confounding
Calvin Yeang, MD, PhD
- The Imminent danger of Lp(a): Time to face to challengePhase II data on Lp(a) lowering, followed by NHLBI recommendation
Prof. Sam Tsimikas
- The Imminent danger of Lp(a): Time to face to challengeLp(a) and calcification in aortic stenosis
Kang He Zheng, MD
- The Imminent danger of Lp(a): Time to face to challengeAssociations of Lp(a) with CV morbidity and mortality
Pia Kamstrup, MD, PhD
- The Imminent danger of Lp(a): Time to face to challengeEntry of Lp(a) into the CV arena
Prof. Florian Kronenberg, MD
- The Imminent danger of Lp(a): Time to face to challengeAre we ready for prime-time Lp(a) assay standardization?
Prof. Santica Marcovina